{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:21Z","timestamp":1793199981419,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IgG4-related ophthalmic disease (IgG4ROD) is a phenotype of IgG4-related disease (IgG4RD) with ophthalmic involvement. The pathological IgG4+ plasmacyte count has only been used for diagnosis. We aimed to explore its possible clinical value in the management of IgG4ROD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty-five pathologically diagnosed IgG4ROD patients were included, and their clinical, pathological, serological, and radiological findings and treatment outcomes were reviewed and analyzed. The pathological IgG4+ plasmacyte counts in lesions from different anatomic sites were compared, and their association with serum IgG4 concentrations, systemic involvement, and relapse risk was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The patients were divided into groups according to the anatomic site of their biopsied lesions, namely, the lacrimal gland, extraocular muscle, and orbital soft tissue. No significant difference was found in the pathological IgG4+ plasma cell counts among these groups (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.975). The pathological IgG4+ plasmacyte count positively correlated with the IgG4 concentration in peripheral blood (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0.5469,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). The serum IgG4 concentration and the pathological infiltrating IgG4+ plasmacyte count were significantly higher in patients with extraophthalmic involvement (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001 and\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005, respectively). The areas under the receiver operating characteristic (ROC) curve (AUCs) of the serum IgG4 level and pathological IgG4+ plasmacyte count for identifying systemic involvement were 0.897 (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and 0.759 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015), respectively. The patients with relapse had higher levels of serum IgG4, more germinal centers (GCs), and infiltrating IgG4+ plasmacytes in lesions. Multivariate Cox regression analysis revealed that a pathological IgG4+ plasmacyte count of &gt;\u2009150\/high-power field (HPF) and an elevated serum IgG4 level of &gt;\u2009500\u2009mg\/dL were risk factors for relapse after steroid treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lesions from different ophthalmic sites in IgG4ROD patients have similar counts of IgG4+ and IgG+ plasmacytes. The quantity of pathological IgG4+ plasmacytes corresponded to the serum IgG4 concentration in patients with IgG4ROD and could be meaningful in identifying systemic involvement and predicting subsequent relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-022-02757-2","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:13:27Z","timestamp":1648793607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yiqun","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"2757_CR1","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385:1460\u201371.","journal-title":"Lancet."},{"key":"2757_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10384-014-0352-2","volume":"59","author":"H Goto","year":"2015","unstructured":"Goto H, Takahira M, Azumi A. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015;59:1\u20137.","journal-title":"Jpn J Ophthalmol."},{"key":"2757_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American college of rheumatology\/European league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77\u201387.","journal-title":"Ann Rheum Dis."},{"key":"2757_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/bjophthalmol-2015-307437","volume":"100","author":"A Wu","year":"2016","unstructured":"Wu A, Andrew NH, McNab AA, Selva D. Bilateral IgG4-related ophthalmic disease: a strong indication for systemic imaging. Br J Ophthalmol. 2016;100:1409\u201311.","journal-title":"Br J Ophthalmol."},{"key":"2757_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/bjophthalmol-2017-311519","volume":"102","author":"JW Hong","year":"2018","unstructured":"Hong JW, Kang S, Song MK, Ahn CJ, Sa HS. Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2018;102:1591\u20135.","journal-title":"Br J Ophthalmol."},{"key":"2757_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","volume":"55","author":"ZS Wallace","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, Kulikova M, Lu L, Deshpande V, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55:1000\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"2757_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/joim.12942","volume":"286","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li JQ, Zhang PP, Zhang X, Peng LY, Chen H, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med. 2019;286:542\u201352.","journal-title":"J Intern Med."},{"key":"2757_CR8","doi-asserted-by":"publisher","first-page":"13341","DOI":"10.1038\/s41598-021-92814-8","volume":"11","author":"I Mizushima","year":"2021","unstructured":"Mizushima I, Konishi M, Sanada H, Suzuki K, Takeji A, Zoshima T, et al. Serum IgG4 levels at diagnosis can predict unfavorable outcomes of untreated patients with IgG4-related disease. Sci Rep. 2021;11:13341.","journal-title":"Sci Rep."},{"key":"2757_CR9","doi-asserted-by":"publisher","first-page":"259408","DOI":"10.1155\/2012\/259408","volume":"2012","author":"MN Carruthers","year":"2012","unstructured":"Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD Responder Index. Int J Rheumatol. 2012;2012:259408.","journal-title":"Int J Rheumatol."},{"key":"2757_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.dld.2011.03.006","volume":"43","author":"H Matsubayashi","year":"2011","unstructured":"Matsubayashi H, Sawai H, Kimura H, Yamaguchi Y, Tanaka M, Kakushima N, et al. Characteristics of autoimmune pancreatitis based on serum IgG4 level. Dig Liver Dis. 2011;43:731\u20135.","journal-title":"Dig Liver Dis."},{"key":"2757_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ajg.2016.40","volume":"111","author":"EL Culver","year":"2016","unstructured":"Culver EL, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 2016;111:733\u201343.","journal-title":"Am J Gastroenterol."},{"key":"2757_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.mpa.0000167000.11889.3a","volume":"31","author":"T Kamisawa","year":"2005","unstructured":"Kamisawa T, Okamoto A, Funata N. Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas. 2005;31:28\u201331.","journal-title":"Pancreas."},{"key":"2757_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1536\/ihj.18-490","volume":"60","author":"R Hourai","year":"2019","unstructured":"Hourai R, Ozawa H, Sohmiya K, Hirose Y, Katsumata T, Daimon M, et al. IgG4-positive plasmacytic infiltration in aortic wall and aortic valve surgical samples and its relation to preoperative serum IgG4 levels. Int Heart J. 2019;60:688\u201394.","journal-title":"Int Heart J."},{"key":"2757_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00417-013-2548-4","volume":"252","author":"Y Sogabe","year":"2014","unstructured":"Sogabe Y, Ohshima K, Azumi A, Takahira M, Kase S, Tsuji H, et al. Location and frequency of lesions in patients with IgG4-related ophthalmic diseases. Graefes Arch Clin Exp Ophthalmol. 2014;252:531\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"2757_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","volume":"25","author":"V Deshpande","year":"2012","unstructured":"Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181\u201392.","journal-title":"Mod Pathol."},{"key":"2757_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1440-1827.2008.02257.x","volume":"58","author":"Y Sato","year":"2008","unstructured":"Sato Y, Ohshima K, Ichimura K, Sato M, Yamadori I, Tanaka T, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int. 2008;58:465\u201370.","journal-title":"Pathol Int."},{"key":"2757_CR17","first-page":"256","volume":"101","author":"YJ Woo","year":"2017","unstructured":"Woo YJ, Kim JW, Yoon JS. Clinical implications of serum IgG4 levels in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2017;101:256\u201360.","journal-title":"Br J Ophthalmol."},{"key":"2757_CR18","doi-asserted-by":"publisher","first-page":"e6205","DOI":"10.1097\/MD.0000000000006205","volume":"96","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Patient M, Grados A, Groh M, Desblaches J, Hachulla E, et al. Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series. Medicine (Baltimore). 2017;96:e6205.","journal-title":"Medicine (Baltimore)"},{"key":"2757_CR19","doi-asserted-by":"publisher","first-page":"109560","DOI":"10.1016\/j.ejrad.2021.109560","volume":"136","author":"AD Dragan","year":"2021","unstructured":"Dragan AD, Weller A, Lingam RK. Imaging of IgG4-related disease in the extracranial head and neck. Eur J Radiol. 2021;136:109560.","journal-title":"Eur J Radiol."},{"key":"2757_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bjophthalmol-2012-302857","volume":"97","author":"YS Song","year":"2013","unstructured":"Song YS, Choung HK, Park SW, Kim JH, Khwarg SI, Jeon YK. Ocular adnexal IgG4-related disease: CT and MRI findings. Br J Ophthalmol. 2013;97:412\u20138.","journal-title":"Br J Ophthalmol."},{"key":"2757_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bjophthalmol-2017-310584","volume":"102","author":"J Park","year":"2017","unstructured":"Park J, Lee MJ, Kim N, Kim JE, Park SW, Choung HK, et al. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2017;102:736\u201341.","journal-title":"Br J Ophthalmol."},{"key":"2757_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nri1714","volume":"5","author":"CG Vinuesa","year":"2005","unstructured":"Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol. 2005;5:853\u201365.","journal-title":"Nat Rev Immunol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02757-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02757-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02757-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:07:47Z","timestamp":1648807667000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02757-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02757-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1301486\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Committee of the Eye & ENT Hospital of Fudan University approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}